companydata.dkAdaptVac ApS: Financial statements 2022
CVR: 38732730
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -1,581,922 and a net result of DKK -4,794,662 compared with DKK -1,781,825 the year before. Equity amounted to DKK 7,762,092. The solvency ratio was 55.4%. The company had 6 employees in the financial year.
- Gross Profit
- -1,581,922 kr.
- Profit/Loss
- -4,794,662 kr.
- Equity
- 7,762,092 kr.
- Total Assets
- 14,014,991 kr.
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -1.6 mio. | -4.8 mio. | 7.8 mio. | 6 |
| 2021 | - | 1.3 mio. | -1.8 mio. | 12.6 mio. | 5 |
| 2020 | - | 20.2 mio. | 15.5 mio. | 15.3 mio. | 3 |
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
| 2018 | - | 432 t. | 334 t. | 64 t. | 0 |
Keep an eye on AdaptVac ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
AdaptVac ApS has published its annual report for 2021. Gross profit came to DKK 1,330,522, and the net result was DKK -1,781,825.
As of May 5, 2022, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of AdaptVac ApS.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.